Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Randomized Trial of PRP vs Intravitreal Ranibizumab Plus Deferred PRP for Proliferative Diabetic Retinopathy
Andrew N. Antoszyk, MD FASRS
Updates from the Field
2016
Episode 131: Journal Club on Follow-up for AMD and PDR Patients, Phase II and III Clinical Trials, Ophthalmology Chairs in the U.S. with Dr. M. Ali Khan
Jayanth Sridhar, MD
Member Podcasts
2018
Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Durga Borkar, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more